Alvaro Roldan-Sevilla

Alvaro Roldan-Sevilla

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 December 2024 in Amyloid
Verified
Journal Article
Closed access
ARAlvaro Roldan-Sevilla
Alvaro Roldan-Sevilla
MGM. Gallego-Delgado
M. Gallego-Delgado
MLM. T. Lista-Araujo
M. T. Lista-Araujo
JTJ. Torres-Pérez
J. Torres-Pérez
AMA. M. Merino-Merino
A. M. Merino-Merino
RER. Eiros-Bachiller
R. Eiros-Bachiller

27 March 2023 in Sleep and Breathing
Verified
Journal Article
Closed access
PDF file
ARAlvaro Roldan-Sevilla
Alvaro Roldan-Sevilla
TCTrinidad Díaz Cambriles
Trinidad Díaz Cambriles
MGMaría Victoria Villena Garrido
María Victoria Villena Garrido
AFAdolfo Fontenla
Adolfo Fontenla
ASAna Isabel Santos Sanchez
Ana Isabel Santos Sanchez
FGF.Javier Garcia-Fernandez
F.Javier Garcia-Fernandez

27 October 2026 in Circulation
Verified
Journal Article
Open access
MGMaría Gallego-Delgado
María Gallego-Delgado
SLSandra Milagros Lorenzo-Hernández
Sandra Milagros Lorenzo-Hernández
SHSoledad García Hernández
Soledad García Hernández
SRSara Rodríguez-Diego
Sara Rodríguez-Diego
David Hansoe Heredero-JungDavid Hansoe Heredero-Jung
David Hansoe Heredero-Jung
MTMario Torrado
Mario Torrado
BACKGROUND: Disruption of MYBPC3 precursor mRNA splicing is a frequent genetic cause of hypertrophic cardiomyopathy (HCM). Most often, it reflects changes at canonical sites or the creation of novel splice sites. Prediction tools usually prioritize splice variants with lower efficiency when they are distant from canonical sites. These elusive variants may explain HCM in patients considered genotype-negative after DNA testing. METHODS: Massively parallel sequencing identified the previously unreported deep-intronic variant MYBPC3 c.2308+227G>A in a cohort of genotype-negative patients with HCM from Salamanca, Spain. SpliceAI predicted a benign effect (Δ score, 0.03). However, its recurrent detection prompted us to conduct extensive analyses to investigate its pathogenicity, including genetic testing, clinical assessment, family studies, splicing assays, and haplotype reconstruction. RESULTS: We identified 35 unrelated HCM probands carrying c.2308+227G>A, plus 46 relatives from 27 families, yielding 81 confirmed carriers. Of these, 56 (69%) met diagnostic criteria for HCM (66% male; mean age, 53±15 years). By age 60 years, cumulative penetrance was estimated to be 81% in women and 96% in men. The combined logarithm of the odds score of 5.51 across 20 informative families provided strong evidence of cosegregation. During follow-up of probands, no significant differences were observed in heart failure, arrhythmic events, atrial fibrillation, or mortality when compared with cohorts carrying other pathogenic MYBPC3 variants. Blood splicing assays, confirmed in cardiac tissue, showed that c.2308+227G>A disrupts splicing by the use of pre-existing cryptic donor (c.2308+299) and acceptor (c.2309−580) splice sites, generating 2 misspliced mRNAs with partial intron retention or cryptic exon inclusion, which encode truncated proteins. These cryptic sites are the leading natural, unannotated missplicing events in intron 23, and some of the most frequent across the whole MYBPC3 precursor mRNA, as revealed by SpliceVault analysis of RNA sequencing databases. This deep-intronic variant does not alter essential splice motifs but promotes the use of pre-existing cryptic sites, likely through gain of splicing regulatory enhancer elements. The identification of a shared haplotype among HCM probands carrying this variant explains its recurrent detection, consistent with an ancient founder effect. CONCLUSIONS: MYBPC3 c.2308+227G>A is a pathogenic splice-altering variant that causes HCM by amplifying natural missplicing events. These background splicing errors help explain how this elusive variant disrupts splicing without creating novel essential splice sites, thereby expanding the known mechanisms by which deep-intronic variants alter MYBPC3 splicing and ultimately contribute to HCM pathogenesis. Elusive MYBPC3 splice-altering variants should be considered in HCM patients with an unresolved genetic origin of disease.

JAJuan Asensio-Nogueira
Juan Asensio-Nogueira
MRMiguel Rodriguez-Santamarta
Miguel Rodriguez-Santamarta
JTJavier Tobar-Ruíz
Javier Tobar-Ruíz
PPPedro Daniel Perdiguero-Martín
Pedro Daniel Perdiguero-Martín
ININES TORANZO NIETO
INES TORANZO NIETO
JPJose-Angel Perez-Rivera
Jose-Angel Perez-Rivera
Introduction and objectives: Acute heart failure (AHF) is the leading cardiovascular cause of hospitalization and remains associated with high mortality and rehospitalization rates. Contemporary real-world data from cardiology departments are scarce. We aimed to identify admission characteristics associated with one-year outcomes in patients hospitalized with AHF. Methods: RECYLICA is a prospective, multicentre, regional registry including consecutive patients admitted with AHF to cardiology departments across 10 hospitals over a one-year period. Patients were followed for 12 months. The primary endpoint was the composite of all-cause mortality or heart failure (HF) rehospitalization. Results: A total of 602 patients were included (37.0% women; mean age 72.6 ± 12.0 years), of whom 47.4% had heart failure with reduced left ventricular ejection fraction (HFrEF). During follow-up, 83 patients (13.8%) died and 105 (17.4%) were rehospitalized because of HF. Independent predictors of the primary endpoint were elevated admission N-terminal pro-B-type natriuretic peptide (NT-proBNP), atrial fibrillation (AF), chronic kidney disease (CKD), chronic obstructive pulmonary disease (COPD), previous HF, prior implantable cardioverter-defibrillator (ICD) implantation, and higher left ventricular ejection fraction (LVEF). Among patients with HFrEF, less comprehensive implementation of guideline-directed medical therapy (GDMT) at discharge was associated with significantly worse outcomes. Conclusions: In patients hospitalized with AHF, prognosis is primarily determined by comorbidity burden, admission NT-proBNP levels, previous HF, and LVEF. Among patients with HFrEF, more comprehensive implementation of GDMT at discharge was associated with improved clinical outcomes, supporting early optimization of evidence-based therapy during hospitalization.